微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 67.3% | 14.55% | 13.61% | 36/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 59.24% | 4.35% | 2.16% | 53/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 57.98% | 1.2% | -6.27% | 55/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 61.86% | 5.95% | 5.29% | 46/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 58.75% | 2.57% | 3.49% | 53/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 56.77% | 21.83% | -0.92% | 61/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 57.29% | 23.33% | -1.87% | 62/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 58.39% | 24.77% | 1.94% | 57/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 57.28% | 16.79% | 22.93% | 56/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 46.59% | 0.91% | 0.3% | 88/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 46.45% | -7.63% | -0.73% | 88/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 46.79% | -11.3% | -4.58% | 88/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 49.04% | -11.73% | 6.21% | 77/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 46.17% | -1.63% | -8.2% | 89/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 50.29% | 1.06% | -4.67% | 78/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 52.76% | 8.79% | -5.04% | 74/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 55.56% | -12.45% | 18.37% | 68/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 46.93% | 1.04% | -5.69% | 88/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 49.76% | 21.23% | 2.61% | 74/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 48.5% | 18.46% | -23.58% | 81/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 63.46% | 63.12% | 36.61% | 40/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 46.45% | 12.66% | 13.16% | 88/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 41.05% | 1.48% | 0.27% | 87/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 40.94% | -8.55% | 5.24% | 94/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 38.9% | -8.81% | -5.66% | 82/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 41.23% | 1.87% | 1.94% | 94/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 40.45% | -5.65% | -9.64% | 74/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 44.77% | 2.3% | 4.94% | 70/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 42.66% | -10.55% | 5.39% | 68/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 40.48% | 32.33% | -5.58% | 92/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 42.87% | 49.31% | -2.03% | 67/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 43.76% | 69.25% | -8.25% | 65/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 47.69% | 81.86% | 55.92% | 58/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 30.59% | 27.63% | 6.53% | 99/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 28.71% | 17.74% | 11.05% | 79/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 25.85% | 7.45% | -1.41% | 88/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 26.22% | 19.35% | 9.42% | 73/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 23.97% | 0.01% | -1.72% | 101/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 24.39% | 2.83% | 1.35% | 71/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 24.06% | 3.31% | 9.51% | 79/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 21.97% | 13.46% | -8.31% | 70/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |